Opendata, web and dolomites

Hemstem SIGNED

Targeting leukaemia by modulating hematopoietic stem cell competitiveness

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Hemstem project word cloud

Explore the words cloud of the Hemstem project. It provides you a very rough idea of what is the project "Hemstem" about.

aml    competitors    wealth    treatment    hematopoiesis    subpopulations    displace    advantages    healthy    severe    similarity    mo    leukemia    immune    survive    molecular    small    chemotherapy    lscs    cell    therapy    stemness    rationale    niche    explores    unable    modify    oncogenic    regulates    leukemic    renewal    strategies    intensity    molecules    im    despite    signaling    resistance    uses    vivo    cells    surviving    bone    bm    home    wnt    zebrafish    expansion    screens    visualize    clinical    lecular    niches    prove    mutations    eradicating    treatments    difficult    decades    patient    human    governing    self    supporting    lsc    costly    evolutionary    fact    transplantation    paradigm    simultaneously    ways    immunotherapy    protective    devastating    malignant    hematopoietic    affinity    conserved    experimental    interactions    shift    myeloid    30    revolutionize    inborn    stem    profiling    homing    diagnosis    disease    mutational    natural    acute    hsc    surveillance    hscs    marrow    patients    inhibit    insights    curative    allogeneic    instead    crude   

Project "Hemstem" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAT BASEL 

Organization address
address: PETERSPLATZ 1
city: BASEL
postcode: 4051
website: www.unibas.ch

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 1˙984˙240 €
 EC max contribution 1˙984˙240 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-COG
 Funding Scheme ERC-COG
 Starting year 2020
 Duration (year-month-day) from 2020-03-01   to  2025-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAT BASEL CH (BASEL) coordinator 1˙984˙240.00

Map

 Project objective

Human acute myeloid leukemia (AML) remains a devastating disease with less than 30% of patients surviving five years after diagnosis. Despite decades of research and detailed mo-lecular insights provided by mutational profiling, curative treatment still requires high-intensity chemotherapy and the crude approach of allogeneic stem cell transplantation – an effective, yet non-specific immunotherapy that is costly to the patient because of its severe side effects. One reason why the wealth of molecular and experimental knowledge has so far been unable to revolutionize treatments is the fact that AML is driven by small subpopulations of so-called leukemic stem cells (LSCs), which survive chemotherapy and immune surveillance. LSCs have growth advantages induced by oncogenic mutations, but are in many ways similar to healthy hematopoietic stem cells (HSCs). This similarity makes it difficult to target LSCs without simultaneously eradicating HSCs and healthy hematopoiesis derived from these cells. Like HSCs, LSCs home to protective bone marrow (BM) niches promoting stemness and therapy resistance and modify them to displace HSCs and promote their own expansion. This proposal explores strategies to target LSCs based on understanding these interactions. In Aim 1 we investigate how WNT signaling, an evolutionary conserved pathway governing stem cell self-renewal, regulates interactions between leukemic and healthy hematopoietic (stem) cells. In Aim 2, we propose to inhibit the in vivo expansion of LSCs by enhancing self-renewal and niche affinity in their natural competitors, the healthy stem cells with inborn BM homing ability. Aim 3 uses zebrafish to visualize LSC-HSC interactions and screens for molecules supporting healthy instead of (pre-) malignant hematopoiesis. Our studies will im-prove the knowledge on the complex interactions between LSCs and HSCs and provide a rationale for novel treatments that might lead to a paradigm-shift in the clinical management of AML.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HEMSTEM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HEMSTEM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

HyperCube (2020)

HyperCube: Gram scale production of ferrite nanocubes and thermo-responsive polymer coated nanocubes for medical applications and further exploitation in other hyperthermia fields

Read More  

PLAT_ACE (2019)

A new platform technology for the on-demand access to large acenes

Read More  

LO-KMOF (2019)

Vapour-deposited metal-organic frameworks as high-performance gap-filling dielectrics for nanoelectronics

Read More